Adaptive Biotechnologies Management
Management criteria checks 2/4
Adaptive Biotechnologies' CEO is Chad Robins, appointed in Sep 2009, has a tenure of 15.17 years. total yearly compensation is $8.90M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth $10.77M. The average tenure of the management team and the board of directors is 5.7 years and 8.8 years respectively.
Key information
Chad Robins
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 7.4% |
| CEO tenure | 15.2yrs |
| CEO ownership | 1.2% |
| Management average tenure | 5.7yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
Compensation vs Market: Chad's total compensation ($USD8.90M) is above average for companies of similar size in the US market ($USD3.14M).
Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.
CEO
Chad Robins (49 yo)
15.2yrs
Tenure
US$8,904,267
Compensation
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 10.8m | |
| President & COO | 6.8yrs | US$2.97m | 0.32% $ 2.8m | |
| Co-Founder & Chief Scientific Officer | 15.2yrs | US$8.61m | 0.69% $ 6.1m | |
| Chief Commercial Officer of Immune Medicine | 6.8yrs | US$2.88m | 0.22% $ 1.9m | |
| Founder | no data | no data | no data | |
| VP, CFO & Principal Accounting Officer | 3.1yrs | US$1.66m | 0.10% $ 916.6k | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP | 5.7yrs | no data | 0.094% $ 826.4k | |
| Chief People Officer | 5.6yrs | no data | 0.17% $ 1.5m | |
| Chief Commercial Officer of MRD | 4.3yrs | no data | 0.17% $ 1.5m | |
| Senior Vice President of MRD BioPharma | 1.2yrs | no data | no data |
5.7yrs
Average Tenure
49.5yo
Average Age
Experienced Management: ADPT's management team is seasoned and experienced (5.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 10.8m | |
| Lead Independent Director | 10.9yrs | US$355.00k | 0.093% $ 818.2k | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Independent Director | 5.7yrs | US$330.00k | 0.035% $ 308.1k | |
| Independent Director | 11.8yrs | US$325.00k | 0.051% $ 450.5k | |
| Independent Director | 6.8yrs | US$310.00k | 0.037% $ 322.0k | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Member of Corporate Advisory Board | no data | no data | no data | |
| Independent Director | 3.7yrs | US$310.00k | 0.038% $ 332.8k |
8.8yrs
Average Tenure
58.5yo
Average Age
Experienced Board: ADPT's board of directors are considered experienced (8.8 years average tenure).